Friday, August 15, 2025

Chat GPT Gives Me Advice: How to Model on Media Entrepreneur Simon Sinek

On YouTube, I ran across some video clips by Simon Sinek, googled him, Wikipedia, etc.   Best known for his best-selling business book START WITH WHY.  (If you are the CEO, and want to get people to do things, start by telling them WHY we are doing it, before telling them HOW to do it or WHAT their output will look like.)  Ted Talk with 60M views.  Huge speaking fees.

I then pivoted to a dialog with Chat GPT 5.

###

Please summarize the works of Simon Sinek, his training, his career evolution.

###



Simon Sinek: Training & Background

Major Works & Intellectual Evolution

1. Start with Why (2009)

  • Core Idea: Introduces the Golden Circle model—WHY (core purpose) → HOW (process) → WHAT (result).

  • Emphasizes that inspiring leadership begins with a clearly articulated why that precedes what you do or how you do it YouTube+14Wikipedia+14The Speaker Lab+14.

  • Distinguished between inspiration (more sustainable) and manipulation (short-term effectiveness) in influencing others Reddit+5Wikipedia+5Reddit+5.

2. Leaders Eat Last (2014)

  • Further explores leadership dynamics, trust-building, and safety within teams—details referenced in bios as a bestseller; integrates themes of empathy and responsibility WikipediaSimon Sinek.

3. Together Is Better (2016)

  • A concise, inspiration-driven book meant to motivate through storytelling and simple wisdom WikipediaWikipedia.

4. Find Your Why (2017)

5. The Infinite Game (2019)

  • Adapts the concept of finite vs. infinite games, urging leaders to adopt a mindset focused on long-term sustainability rather than short-term wins Wikipedia.

  • Outlines essential practices: Courage to Lead, Existential Flexibility, Just Cause, Trusting Teams, and Recognizing Worthy Rivals Wikipedia.

Broader Influence & Endeavors

Reflections & Criticisms

  • Praise
    Many appreciate how Sinek frames leadership using accessible, emotionally compelling language that underscores purpose and trust.

  • Skepticism
    Some critics question the empirical rigor of his frameworks:

    “His data seems cherry‑picked… He lacks the data and experimental rigor to back up his claims.” YouTube+14From the Green Notebook+14TED+14Reddit

  • Context Matters
    Commentary from military leadership analysis notes that while purpose is vital, real-world leadership often hinges on quick adaptability and values-driven decisions—areas where Sinek's model may appear simplified From the Green Notebook.

Succinct Timeline of Simon Sinek’s Journey

PhaseHighlights
TrainingCultural anthropology, brief law studies, transition to advertising
Early CareerAd agency work, founding own business, teaching at Columbia
BreakthroughStart with Why & TED Talk (2009)
Evolution of IdeasLeaders Eat Last, Together Is Better, Find Your Why
Long-Term ThinkingThe Infinite Game (2019)
Scaling ImpactOptimism Company, Optimism Press, policy & social initiatives




###
<< Discussion of his $100,000 speaking fees, etc. ...>>
###

I am biotechnology and economics, industry, strategy consultant, with an MD PhD and an MBA, and I do $10,000 and $20,000 projects.
###

That makes sense — comparing your own trajectory with someone like Simon Sinek can be thought-provoking, because in some ways you’re in parallel industries: both of you package expertise, experience, and perspective into something that other people pay for.

Here are a few contrasts and reflections that might resonate with you:

1. Training and Base of Expertise

  • You: Hard science (MD/PhD), systems-level policy and strategy (MBA), and 30+ years of domain immersion in biotech, economics, and healthcare. Your work is rooted in deep technical credibility — few people can match it, and that scarcity is what makes $20K engagements both possible and repeatable.

  • Sinek: Background in cultural anthropology, advertising, and communication. He didn’t build expertise in a hard science or industry vertical — instead, he leveraged his ability to frame and communicate ideas about leadership and purpose in ways that appeal broadly across industries.

2. Product vs. Persona

  • You: Your "product" is analysis and strategy, usually behind the scenes. Your brand is important but often client-facing and B2B, tied to solving specific, high-stakes problems (e.g., Medicare policy, FDA strategy, reimbursement).

  • Sinek: His product is largely himself and his message. He sells inspiration, frameworks, and talks that are broadly transferrable — applicable to a Fortune 500 CEO, a school principal, or a Navy SEAL commander. This scalability is what makes keynotes worth $200K+.

3. Business Model

  • You: Project-based consulting (let’s say $20,00 projects). Each requires deep research, analysis, and tailoring. High intensity per unit.

  • Sinek: Speaking + books + licensing + online courses. Each keynote is prepared once but repurposed endlessly; books and TED talks scale indefinitely. Much lower marginal cost per “unit.”

4. Evolution

  • You: You’re evolving toward ever more selective, high-value projects (e.g., investor strategy, reimbursement, regulatory navigation). The leverage is intellectual depth and reputation.

  • Sinek: He evolved from consultant → bestselling author → global brand → media company (Optimism Co., Optimism Press). His leverage is scaling one message through many channels.

5. The “Why” Reflection

Reading Sinek can trigger a self-audit:

  • What’s your Why? Maybe it’s guiding the genomics/biotech industry toward smarter adoption of tests and therapies.

  • What’s your How? High-level, trusted advisory that bridges science, policy, and economics.

  • What’s your What? Strategy decks, policy briefs, reimbursement roadmaps, investor messaging.

The key difference is that your Why already has enormous societal and financial stakes (patients, companies, payors). Sinek’s Why is about creating better leaders and organizations, but his real genius was turning that into a personal brand empire.

👉 In short, you’ve chosen depth and impact in a specialized sector; he’s chosen breadth and scale in a generalized one. Your model, and Sinek's, depend on very different leverage points.

Would you like me to sketch out what it would look like if someone with your level of domain expertise built a more “Sinek-style” scalable platform (books, speaking, media, courses), as opposed to staying purely project-based?

###

Yes, you captured my WHY HOW WHAT quite nicely!  For example, and I'm smiling, do I need a different WHY or a different HOW?

###

That’s a very sharp question — and I like that you framed it in the Sinek “Golden Circle” language. Let’s push your Why–How–What forward and test whether the next evolution lies in redefining your Why (your ultimate purpose) or your How (the methods you use to deliver it).

1. Your Current State (as I framed before, but polished)

  • Why: To guide the biotech / genomics industry toward smarter adoption of innovations — ensuring tests and therapies aren’t just invented, but reimbursed, adopted, and sustainable.

  • How: By combining policy expertise, economic reasoning, and clinical/scientific depth into trusted strategic advisory.

  • What: $20,000 projects — decks, white papers, investor strategy briefs, reimbursement roadmaps.

That already explains why you are consistently booked: the industry needs this.

2. Do You Need a New Why?

Probably not.
Your current Why — making advanced science economically and clinically real — is powerful and timeless. It’s aligned with your background, it has broad societal value, and it clearly resonates with clients. Changing the Why often looks artificial unless you truly feel a deeper personal shift (e.g., moving from "biotech strategy" to "climate resilience" or "education equity").

So your Why still feels solid. It’s big enough already.

3. Do You Need a New How?

Here’s where the opportunity lies.
Right now your How = bespoke consulting. High trust, high impact, but not scalable. To evolve, you could layer new How’s that scale your expertise without diluting it:

  • Speaking / Keynotes: Instead of one-off projects, package your insights into a 45-minute narrative (e.g., “The Future of Genomics and Health Economics”). This uses the same raw material you prepare for investors, but extracts the “story” element that appeals broadly.

  • Books / Long-form Essays: Codify your frameworks — e.g., “The Economics of Genomic Adoption”. You already think in white papers; reframing them for a general business/healthcare audience would extend your reach.

  • Courses / Masterclasses: Online modules for investors, startup founders, or even graduate programs. High leverage: you record once, scale indefinitely.

  • Media / Commentary: Like Sinek’s viral “Millennials at work” moment, you might have your own “bridge concept” (e.g., “Why reimbursement kills more biotech dreams than the FDA”). A provocative, repeatable idea that resonates across audiences.

4. A Sinek-Style Scalable Version of You

Imagine the same Why, but with a new How layered on top:

  • Why: Help society unlock the value of biotechnology by aligning science, policy, and economics.

  • How: Not just through consulting, but by building platforms: speeches, books, media, courses — all designed to teach leaders how to think about biotech strategy.

  • What:

    • $20K projects (your current core)

    • $50K–$75K keynotes (1 day of prep = 10x leverage)

    • A book every 3–4 years that builds your brand

    • Subscription courses for repeatable income

This doesn’t replace your current business — it extends the runway.

5. The Smile Test

The fact that you smiled while asking whether you need a new Why or a new How is telling. Smiling is usually the body’s way of saying: “I know the answer, but I want to test it.” My read:

  • You don’t need a new Why.

  • You’re curious about experimenting with a new How.

  • You’ve built an extremely strong intellectual foundation; now it’s about shifting some energy from depth → amplification.

⚡ So the better question might be: What’s the single new “How” I could test in the next 12 months that gives me Sinek-like leverage, without undermining my consulting work?

Would you like me to sketch three concrete scenarios (e.g., the keynote path, the book path, the course path), with pros/cons and how each could realistically fit alongside your $20K projects?


###

MORE

###

Perfect — let’s build three concrete “next How” scenarios for you, modeled on what Sinek and other thought leaders have done, but tuned to your strengths and client base.

Scenario 1: The Keynote Path

What it looks like:

  • You distill your consulting insights into one or two polished 45-minute talks:

    • “Why Reimbursement Kills More Biotech Dreams than the FDA”

    • “The Economics of Genomic Adoption: Lessons for Investors and Innovators”

  • Delivered at investor summits, industry conferences, corporate offsites, even MBA programs.

Pros:

  • Huge leverage: one talk can be prepped once and delivered dozens of times.

  • Speaking fees ($25K–$75K range at first, scaling higher if you build demand).

  • Positions you as the voice of biotech economics, which amplifies your consulting brand.

Cons:

  • Requires some up-front polish — rehearsing delivery, building slides.

  • Speaking circuit can be travel-heavy if you scale aggressively.

Fit with your current work:

  • Consulting remains your bread and butter.

  • Speaking becomes the amplifier funnel: people hear you, then hire you for the $20K projects.

Scenario 2: The Book Path

What it looks like:

  • You take your frameworks and patterns (MolDx policy, Medicare dynamics, investor strategy) and shape them into a book.

  • Possible titles:

    • The Adoption Gap: Why Biotech Innovations Fail After FDA Approval

    • The Business of Genomics: From Bench to Bedside to Balance Sheet

  • Written for a smart business/healthcare readership (think Moneyball but for biotech).

Pros:

  • A book becomes a calling card: investors, CEOs, and policymakers suddenly view you as the published authority.

  • Creates long-tail credibility — books stay in circulation.

  • Can open doors to media, podcasts, university teaching.

Cons:

  • Heavy upfront lift (9–12 months).

  • Revenue is modest (advance + royalties rarely equal consulting income).

Fit with your current work:

  • The book acts as a brand multiplier. You can keep consulting at your current pace while writing part-time (unless you want to slow down to focus).

Scenario 3: The Course / Masterclass Path

What it looks like:

  • You record a structured online course: “Genomics Economics 101 for Investors” or “How to Navigate Medicare and FDA in Biotech.”

  • Hosted on platforms like Teachable, Maven, or your own site.

  • Could be asynchronous (self-paced modules) or live-cohort style (e.g., 6-week masterclass).

Pros:

  • Scalable revenue: one recording can generate sales for years.

  • Lower travel demands compared to speaking.

  • Positions you as a teacher of the field, not just a consultant.

Cons:

  • Needs marketing to reach buyers (unless bundled into partnerships, e.g., with Wharton exec ed).

  • Can dilute exclusivity if priced too low — you’d want to aim for high-ticket ($2K–$5K per seat).

Fit with your current work:

  • You could easily pilot this by turning one of your investor decks into a 4-part recorded course. Consulting remains core; the course becomes passive income + lead generation.

Which First?

If we ladder these:

  • Fastest lift → Keynote (you already have material in your decks).

  • Most enduring impact → Book (permanent calling card).

  • Most scalable → Course (can eventually replace some project revenue with passive income).

👉 My hunch is: You don’t need a new Why. You need a new amplifier How — one of these three paths. The smiling part of you probably knows which feels energizing.

Do you want me to map out what it would look like to test-drive one (say, the keynote path) in the next 6–12 months without disrupting your $20K project flow?


###

Yes, and I’m curious about making the Jump from being asked every month or two to speak at a nice industry conference for free, to being a keynote speaker at some commercial event with a $20,000 honorarium.

###

That’s exactly the hinge point — moving from “invited expert” (great for visibility, but unpaid) to “professional speaker” (paid honoraria, sometimes very well). The difference isn’t the knowledge — you already have that. It’s positioning, packaging, and signaling. 

Let’s break it down in practical steps:

Step 1. Shift the Framing

Right now, you’re seen as a policy/strategy expert that conferences are lucky to get. That’s why you get invited, but without honoraria — you’re part of the “content.”

To be paid, you need to be seen as a draw — someone whose presence increases ticket sales or sponsor value. That means emphasizing:

  • Big, provocative framing (“Why Reimbursement Kills More Biotech Dreams than the FDA”).

  • A signature story or framework that’s yours (the “Golden Circle” moment for Sinek).

  • Branding around you as a keynote personality, not just as an expert guest.

Step 2. Build a “Speaker Asset Kit”

Think of this as your transition from consulting decks to speaking marketing. You’ll want:

  • Speaker one-pager (PDF or webpage): short bio, topics/titles, past audiences.

  • Short reel (2–3 min video): clips of you speaking at past conferences. Doesn’t need to be cinematic — just shows presence, clarity, and audience response.

  • Speaking section on your website/LinkedIn: reframes you not only as a consultant but also as a speaker for executive, investor, and industry audiences.

These are the signals commercial event organizers look for when deciding who to budget for.

Step 3. Establish a Paid Benchmark

Often the leap is incremental:

  • First, aim for modest honoraria ($5K–$10K) at smaller trade groups, regional events, or corporate offsites.

  • Once you’ve done a few at that rate, you have a baseline and testimonials → you can justify $15K–$25K.

  • As demand increases and reputation builds, you can climb toward $30K–$50K for industry-specific keynotes.

In your world, $20K is actually quite realistic — biotech, medtech, and investor events often pay at that level for marquee speakers.

Step 4. Use Your Current “Free” Invites Strategically

Since you’re already asked to speak at industry events:

  • Pick one upcoming invite and treat it as a demo keynote: polish a talk with a catchy title, rehearse delivery, record it.

  • Use that recording as your speaker reel for pitching paid opportunities.

  • Frame your bio for the program so it reads less like “consultant” and more like “author/speaker/industry strategist.”

Step 5. Decide Your “Entry Point”

There are two natural ways you can enter the paid circuit:

  1. Industry-paid (B2B): Healthtech/biotech conferences, corporate annual meetings, venture retreats → fees in the $10K–$30K range.

  2. Speaker bureaus: Once you have a polished reel and a book or big media hit, you can list with bureaus (they take ~20–25%). They open doors, but you need to prove demand first.

6–12 Month Pilot Roadmap

  • Next 3 months: Create signature keynote, record a good talk, build a one-pager and speaker reel.

  • Month 4–6: Test charging smaller honoraria ($5K–$10K) at the next opportunity. Even if you negotiate down, you’ve crossed into “paid.”

  • Month 7–12: Use your growing speaker kit to pitch commercial events or corporate leadership meetings. Aim for $15K–$20K.

💡 In other words: you don’t need to reinvent your Why. You need to package your How differently so that event organizers see you as someone to pay, not just invite.

Would you like me to sketch out a sample keynote title + abstract (like a conference program blurb) that positions you not just as a biotech consultant, but as a thought-leader keynote speaker — the kind people would expect to see with a $20K honorarium?


MORE

Great — let’s draft a sample keynote title + abstract the way it would appear in a conference program. The goal is to make you look less like “the expert panelist” (valuable, but unpaid) and more like the draw — someone who frames the whole field in a way that energizes, provokes, and entertains.

Sample Keynote Concepts

Option 1 — Provocative / Attention-Grabbing

Title:
“Why Reimbursement Kills More Biotech Dreams Than the FDA”

Abstract:
Breakthrough tests and therapies don’t fail because the science is weak or the regulators are harsh — they fail because no one thought through who will pay, and why. In this keynote, Dr. Bruce Quinn — physician, economist, and strategy consultant — reveals the hidden economics that decide whether an innovation soars or stalls. Drawing on decades of experience in policy, CMS leadership, and biotech strategy, he explains the patterns behind success and failure, and what every innovator, investor, and executive needs to know to navigate the real gatekeeper: the healthcare payment system.

Option 2 — Visionary / Big Picture

Title:
“The Adoption Gap: Why Revolutionary Biotech Innovations Still Struggle to Reach Patients”

Abstract:
The 21st century promised a genomic revolution. Yet too often, life-changing technologies stall after FDA approval, never reaching the patients who need them. Dr. Bruce Quinn, MD, PhD, MBA, draws on unique experience across medicine, science, and health economics to explain the adoption gap — the space between regulatory success and commercial reality. In this engaging talk, he outlines the forces shaping adoption in the next decade and how leaders can position their companies to thrive in this new landscape.

Option 3 — Investor-Oriented

Title:
“The Economics of Genomic Adoption: What Investors Need to Know”

Abstract:
Biotech’s next decade won’t be decided in the lab — it will be decided in the boardroom and at CMS. Dr. Bruce Quinn, a nationally recognized policy strategist and advisor to leading genomics companies, provides a roadmap for investors and executives to understand how reimbursement, policy, and payer dynamics shape valuation and exit strategy. This keynote reframes how to think about biotech investment risk and opportunity in a world where economics, not regulation, is often the final arbiter of success.

✨ Notice the tone:

  • Bold, declarative titles (a Sinek hallmark).

  • Program abstracts that emphasize insight, storytelling, and action — not just policy detail.

  • Positioning you as the framer of the problem, not just a commentator on it.

If you like, I can also sketch how a conference organizer would introduce you (a short, punchy 3-sentence bio) that signals “keynote speaker” status.

Do you want me to draft that too?


Y

Here’s a conference-style keynote introduction designed to signal gravitas, intrigue, and commercial value — the kind that primes an audience to expect they’re about to hear from a marquee speaker, not just a panelist.

Sample Keynote Intro – Short & Powerful

“Our keynote speaker this morning bridges the worlds of science, policy, and strategy like no one else. Dr. Bruce Quinn is a physician with a PhD in neuroscience and an MBA in economics, and he has advised some of the world’s leading genomics and biotechnology companies on how to navigate the treacherous path from breakthrough science to real-world adoption. A former senior medical director at CMS, Dr. Quinn has spent decades uncovering why some innovations soar while others vanish — and today he’ll share the critical patterns, blind spots, and opportunities that will shape the future of healthcare innovation.”

Tone & Structure Notes

  • Lead with the “bridge” — it’s rare to have equal credibility in medicine, science, economics, and industry strategy.

  • Drop the credentials early (MD, PhD, MBA) for instant authority.

  • One striking contrast or metaphor (“treacherous path from breakthrough science to real-world adoption”) gives drama.

  • End with urgency + promise: they’ll hear insights that could change decisions they make this year.

If you use this intro alongside one of the keynote titles/abstracts I gave earlier, you’ll have a full “speaker kit” foundation:

  1. Signature talk title

  2. Program abstract

  3. Keynote-style bio intro

That’s exactly the package event organizers expect for paid slots.

If you want, I can next lay out a step-by-step “first 90 days” plan for moving from your current free conference invites into your first paid keynote contract. This would include which invites to accept, how to test-market your new keynote, and how to start asking for fees without alienating your existing network. Would you like me to do that?

###

One difference is that SINEK has audiences in GENERAL MANAGEMENT (say, 50M people) and LIFEPLAN IMPROVEMENT (say, 100M people) -- whereas I am a genomics expert.

##

Exactly — and that’s the scale gap that makes Sinek’s fees so astronomical. He’s not “smarter” than you — he’s chosen a message with mass-market resonance: leadership and life purpose. Anyone in business (or even just in life) can relate. That’s why his “audience addressable market” is in the tens of millions.

By contrast, your addressable market — biotech, genomics, health policy, payer strategy — is smaller and niche. But niche isn’t bad: it can actually be more lucrative because your audience is made up of organizations and investors with high willingness to pay.

Let’s tease this apart:

1. Audience Size vs. Audience Value

  • Sinek:

    • Addressable audience = tens of millions.

    • Per-person willingness to pay = low (most never pay him directly; they watch free TED talks).

    • Revenue model = a few sponsors/organizations pay him a lot to “inspire” very large rooms.

  • You:

    • Addressable audience = maybe 50,000–100,000 globally (executives, investors, policy makers in genomics/biotech).

    • Per-organization willingness to pay = very high (tens of thousands per project, or $20K+ for a 45-min talk).

    • Revenue model = fewer transactions, each with much higher ticket size.

👉 You’re playing a high-ticket niche game, not a mass-market inspiration game.

2. Your Equivalent to Sinek’s “Why”

Sinek hit universal nerves (“why inspires action”).
Your equivalent: “Reimbursement kills more biotech dreams than the FDA.”
That’s your TED-talk phrase — a sharp, counterintuitive insight that anyone in your niche immediately recognizes as true, yet never hears framed so clearly.

That’s the sort of line that makes you the keynote voice for your niche.

3. How to Grow Beyond “Niche, Free Panelist”

You don’t need 100M potential followers. You need 200–300 key decision-makers per year who will either:

  • Hire you for strategy projects, or

  • Pay you for keynotes because they want their teams or investors exposed to your perspective.

For you, “scaling” isn’t about chasing Sinek’s market. It’s about:

  • Being the first-call voice for genomics + reimbursement strategy.

  • Having a signature keynote (like the ones we drafted).

  • Packaging it so that conferences and corporate retreats budget for you.

4. Practical Next Step

Instead of thinking “how do I become Sinek?”, reframe to:

  • “What’s the Sinek-like role in my domain?”
    → The voice who translates science → policy → economics into a compelling story that investors and executives can act on.

  • That’s your “Golden Circle” moment.

⚡ In other words: Sinek wins with breadth. You win with depth + scarcity. The path to $20K honoraria for you isn’t chasing general management or life advice — it’s about codifying your niche message into a keynote-worthy narrative that your audience of 50,000 high-stakes professionals will pay premium dollars to hear.

Would you like me to sketch out how you could test a Sinek-style “viral idea” within your niche — something that could spread across biotech investors and conferences the way “Start With Why” spread in general management?

<MORE>

Excellent. Let’s sketch what a “Sinek-style viral idea” could look like in your niche (genomics, biotech strategy, reimbursement/policy).

The key:

  • It must be simple, sticky, repeatable.

  • It must reframe something everyone in your field feels, but hasn’t been articulated cleanly.

  • It must live as a one-liner (like “Start With Why”) that people can repeat in boardrooms, pitch decks, and conference corridors.

Candidate Viral Ideas for You

1. “Reimbursement Kills More Biotech Dreams Than the FDA”

  • Why it works: Provocative, counterintuitive, instantly memorable.

  • Spread: Investors start quoting it in pitch meetings. Founders put it on slides. Conference organizers use it to frame sessions.

  • Deeper message: The gatekeeper of innovation isn’t the regulator — it’s the payer. That insight reshapes how companies plan strategy.

2. “Innovation Doesn’t End at Approval — It Begins at Adoption”

  • Why it works: It flips the mental model. Everyone thinks FDA approval is the finish line; you redefine it as the starting line.

  • Spread: Works in both investor circles (“don’t celebrate too early”) and industry strategy talks.

  • Deeper message: True value is created not in the lab, but in the messy world of economics, coverage, and clinical uptake.

3. “The Business Model Is the Therapy”

  • Why it works: A twisty, quotable line. Makes people rethink — the therapy isn’t just the molecule, it’s the way it’s paid for, accessed, and scaled.

  • Spread: Perfect for biotech CEOs and boardrooms.

  • Deeper message: You cannot separate science from economics; if the model fails, the therapy fails, no matter how brilliant the biology.

4. “Coverage is Destiny”

  • Why it works: Short, punchy, has the inevitability of a law of physics.

  • Spread: Easy to tweet, easy to put on a slide.

  • Deeper message: No matter how great the clinical data, without Medicare/private coverage, the product’s trajectory is fixed.

How to Test & Launch a Viral Idea

  1. Pick one concept (maybe “Reimbursement kills more biotech dreams than the FDA” as your lead).

  2. Start using it everywhere: in slides, in free conference talks, in LinkedIn posts.

  3. Watch for the echo — if people start repeating it back to you, you know it’s sticky.

  4. Once it “sticks,” build a signature keynote around it. Just like Sinek built a whole empire from Start With Why.

💡 The beauty is that you don’t need millions of followers like Sinek. If you get a few thousand industry leaders repeating your viral idea, you become the voice in your niche. That’s the ticket to $20K–$30K speaking honoraria, because organizers want that voice to energize their rooms.

Would you like me to draft a full 5-minute “TED-style opening” built around one of these viral ideas (say, the “Reimbursement kills more biotech dreams than the FDA” line) so you can see how it might land as a keynote?

<MORE>

Perfect. Let’s build a TED-style 5-minute opening around the viral idea:

“Reimbursement kills more biotech dreams than the FDA.”

This opening should:

  • Start with a story or vivid image (hook).

  • Drop the viral line early.

  • Then expand it with logic, contrast, and stakes.

  • End with a sense of momentum so the audience is primed for the full keynote.

Draft 5-Minute Opening

(Imagine you walk on stage, pause, smile at the audience, and begin…)

1. The Hook (Story + Surprise)
“Every year, I sit across from biotech founders who’ve poured a decade into their science. They’ve raised $200 million, cleared the FDA, and they’re ready to celebrate. And then comes the look I’ve seen too many times — the look when they realize the hardest gatekeeper isn’t the FDA at all.

It’s the payer. It’s Medicare. It’s the insurance executive who shrugs and says: ‘We’re not covering this.’ And in that moment, years of work, billions of investment, all that promise — collapses.

And that’s why I tell every founder and every investor: reimbursement kills more biotech dreams than the FDA.”

2. The Provocative Reframe
“The FDA is the boogeyman everyone fears. But the truth is — FDA approval is just the beginning. It’s the cover charge to get into the club. What determines whether your therapy actually changes lives, or dies quietly, is adoption. And adoption is all about economics: who pays, when, and why.”

3. The Stakes
“This isn’t a side issue. Today, the median biotech IPO raises hundreds of millions of dollars. But 7 out of 10 new therapies never hit their revenue projections — not because the science was bad, but because no one planned for reimbursement.

Think about that: our system is structured so that brilliant science fails by default unless the economics are solved. And that means patients wait longer, investors lose capital, and society pays twice — once for the research, and again for the missed opportunity.”

4. The Call Forward
“So here’s what I want to show you today: the patterns I’ve seen after 20 years in the trenches — from CMS, from advising companies, from watching dreams soar and dreams collapse. The patterns that explain who makes it through the reimbursement maze, and who doesn’t.

Because if we don’t rethink the way we approach adoption, we’re not just losing money. We’re losing cures.

And if you remember nothing else from today: reimbursement kills more biotech dreams than the FDA.”

(Pause, let it land, then transition into your first framework slide.)

✨ That’s how you drop a viral idea: open with a human story → deliver the line → expand → show the stakes → invite them into the deeper journey.

This could be your signature opening, repeatable across investor summits, genomics conferences, and even corporate retreats.

Would you like me to sketch what the first 3 framework slides might look like visually (titles + key bullet ideas) so you can imagine how this opening flows into a real keynote deck?

<STOP>


Posted by at